Aplastic Anemia - Epidemiology Forecast - 2036

Aplastic Anemia Insights and Trends

• Aplastic anemia is a rare and severe non-malignant disease characterized by autoimmune destruction of early hematopoietic cells. Its global incidence rate ranges from 0.7 to 7.4 cases per million inhabitants per year, with higher rates in Asia compared to Europe and the United States.
• In many cases, the cause of aplastic anemia is unknown (idiopathic). It can also be acquired due to factors such as exposure to toxins, infections, medications, or as a secondary condition associated with autoimmune diseases.
• As per NORD, acquired aplastic anemia affects males and females in about equal numbers. Most cases affect older children, teenagers, or young adults.
• The historical terminology of "aplastic anemia" may be misleading, as it is an acquired marrow failure syndrome characterized by peripheral pancytopenia and hypoplastic bone marrow.
• Based on severity, severe and very severe aplastic anemia patients contribute roughly 65%-80% of the total aplastic anemia patient population.

DelveInsight's 'Aplastic Anemia - Epidemiology Forecast - 2036' report delivers an in-depth understanding of Aplastic Anemia, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Aplastic Anemia Understanding and Diagnosis Algorithm

Aplastic Anemia Overview

Aplastic Anemia is characterized by pancytopenia with a hypocellular bone marrow, excluding marrow failure secondary to chemotherapy or radiotherapy. The lack of pathognomonic markers complicates diagnosis, which depends on marrow histology demonstrating diminished cellularity with fatty infiltration and systematic exclusion of alternative causes. Emerging evidence implicates mechanisms such as accelerated telomere shortening, acquired mutations in myeloid-associated genes, clonal hematopoiesis, and dysregulated cytokine milieus in disease pathogenesis. The clinical manifestations arise from inadequate hematopoiesis, with symptom severity varying widely. Some individuals remain mildly affected and stable for years, whereas others develop progressive, potentially life-threatening complications.

Aplastic anemia is broadly classified into congenital and acquired types. Inherited variants are uncommon and encompass Fanconi anemia, dyskeratosis congenita, congenital pure red cell aplasia, and Shwachman-Diamond syndrome.

Aplastic Anemia Diagnosis

Aplastic anemia is diagnosed through a structured integration of clinical presentation, hematologic findings, and bone marrow evaluation, with emphasis on excluding secondary and reversible causes at the outset. Patients commonly present with manifestations of pancytopenia, including fatigue from anemia, recurrent infections due to neutropenia, and bleeding or bruising related to thrombocytopenia, prompting initial laboratory assessment that reveals reduced counts across all three cell lines, accompanied by a low reticulocyte count, indicating diminished marrow production. Definitive diagnosis is established by bone marrow aspiration and biopsy demonstrating a markedly hypocellular marrow with replacement by fat and absence of malignant infiltration or significant fibrosis. Contemporary diagnostic approaches require systematic evaluation for underlying etiologies, including drug or toxin exposure, viral infections, autoimmune disorders, and inherited bone marrow failure syndromes, particularly in younger individuals, alongside screening for paroxysmal nocturnal hemoglobinuria clones given its clinical overlap. Severity assessment, based on the depth of cytopenias and marrow cellularity, is essential for guiding management decisions. Current recommendations also highlight the importance of early specialist referral, HLA typing at diagnosis, and incorporation of molecular testing to identify clonal abnormalities that may influence prognosis and risk of progression to myelodysplastic syndromes or acute leukemia, ensuring a comprehensive and analytically grounded diagnosis.

Aplastic Anemia Epidemiology

Key Findings from Aplastic Anemia Epidemiological Analysis and Forecast

• As per DelveInsight estimates, the total incident population of aplastic anemia in the 7MM was around 2,600 cases in 2025. These cases are projected to increase during the forecast period.
• Japan accounted for the highest Incident cases of aplastic anemia in the 7MM in 2025, with approximately 850 cases.
• In the United States, it is observed that aplastic anemia occurs primarily in the age group of 60 years and above, accounting for ~56% of all cases, in 2025.
• Among EU4 and the UK, Germany accounted for the highest number of aplastic anemia cases, followed by France, whereas Spain accounted for the lowest number of cases in 2025.
• Among the severity-specific cases, Severe Aplastic Anemia (SAA) was more common in the United States, with ~430 cases in 2025.

Scope of the Report:

• The report covers a segment of an executive summary, a descriptive overview of Aplastic Anemia, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Aplastic Anemia Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by Geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of Aplastic Anemia? What will be the growth opportunities across the 7MM concerning the patient population with Aplastic Anemia?
• What is the historical and forecasted Aplastic Anemia patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.